Thrombotic Thrombocytopenic Purpura (TTP) - Market Insights, Epidemiology and Market Forecast-2027

albany, new york -- (SBWire) -- 02/08/2019 --Thrombotic Thrombocytopenic Purpura (TTP) - Market Insights, Epidemiology and Market Forecast-2027

08 Feb. 19

There were approximately 10,200 prevalent cases of TTP in 2016 in the 7MM. These prevalent cases are further expected to increase.

- The United States accounts for the highest prevalent population of Thrombotic Thrombocytopenic Purpura, followed by the EU5 and Japan
- Among the European countries, Germany had the highest prevalent population of TTP with 1200 cases, followed by France with around 800 cases, in 2016. Spain had the lowest prevalent pool of TTP in 2016
- Japan had the lowest prevalent population of TTP in 2016 with 500 cases

(Albany, US) DelveInsight launched a new report on Thrombotic Thrombocytopenic Purpura (TTP) - Market Insights, Epidemiology and Market Forecast-2027

Request for sample pages

Key topics covered

- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Thrombotic Thrombocytopenic Purpura market.
- Organize sales and marketing efforts by identifying the best opportunities for Thrombotic Thrombocytopenic Purpura market.
- To understand the future market competition in the Thrombotic Thrombocytopenic Purpura market.

"The majority of acute cases of TTP is acquired auto-antibody mediated, characterized by low ADAMTS13 activity (<10%) and the presence of antiADAMTS13 IgG antibodies. A small proportion of TTP cases is due to the congenital disease, with low ADAMTS13 activity (<10%) and no detectable antibody. Amongst type-specific TTP, there are about 9,700 prevalent cases of acquired TTP, while there are only 513 cases of congenital TTP in the 7MM."

Market analysis carried out for the period of 2016-2027 showed that the market size of Thrombotic Thrombocytopenic Purpura (TTP) will be USD 20 million in 2019 in the 7MM. Till now, Therapeutic Plasma Exchange (TPE) remains as the cornerstone of management of TTP. Besides TPE, the standard first-line therapy may include steroids (prednisone or IV prednisolone) and anti-platelet agents. Aspirin and Dipyridamole are the two main anti-platelets considered potentially effective for the treatment of TTP. However, no study has provided definitive evidence of their efficacy. Among these therapies, many patients experience a relapse within one-year period. Thus, considering the relapse prevention, increasing evidence supports the use of the anti-CD20 monoclonal antibody Rituximab in cases of TTP refractory to plasma exchange, with resolution of acute disease and prolonged remission. Besides all these therapies, there is a high unmet need for novel treatment options that would result in faster resolution of the acute episode of aTTP (acquired TTP) and the related resulting organ damage, reduction in risk of mortality and thromboembolic events, prevention of recurrences while on treatment, reduction in risk of refractoriness to treatment and reduction in dependency on TPE. Thus, various companies are shifting their focus for the development of novel therapies, and consequently the dynamics of the TTP market is anticipated to change during the forecast period (2018-2027). Recent marketing authorization of the first aTTP therapeutic Cablivi (Nanobody based medicine) may provide a better option for the patients struggling with less responsive limited treatment choices.

Companies covered
- Sanofi
- Shire
And many others

Drugs covered
- Cablivi (caplacizumab)
- SHP-655
And many others

Table of contents
1. Report Introduction
2. Thrombotic Thrombocytopenic Purpura Market Overview at a Glance
2.1. Market Share Distribution of Thrombotic Thrombocytopenic Purpura in 2017
2.2. Market Share Distribution of Thrombotic Thrombocytopenic Purpura in 2027
3. Disease Background and Overview: Thrombotic Thrombocytopenic Purpura
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Thrombotic Thrombocytopenic Purpura in 7MM
4.3. Total Prevalent Patient Population of Thrombotic Thrombocytopenic Purpura in 7MM – By Countries
5. Epidemiology of Thrombotic Thrombocytopenic Purpura by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Thrombotic Thrombocytopenic Purpura
5.1.3. Sub-Type Specific cases of the Thrombotic Thrombocytopenic Purpura
5.1.4. Sex- Specific Cases of the Thrombotic Thrombocytopenic Purpura
5.1.5. Diagnosed Cases of the Thrombotic Thrombocytopenic Purpura
5.1.6. Treatable Cases of the Thrombotic Thrombocytopenic Purpura
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Thrombotic Thrombocytopenic Purpura
5.4.3. Sub-Type Specific cases of the Thrombotic Thrombocytopenic Purpura
5.4.4. Sex- Specific Cases of the Thrombotic Thrombocytopenic Purpura
5.4.5. Diagnosed Cases of the Thrombotic Thrombocytopenic Purpura
5.4.6. Treatable Cases of the Thrombotic Thrombocytopenic Purpura
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Thrombotic Thrombocytopenic Purpura
5.5.3. Sub-Type Specific cases of the Thrombotic Thrombocytopenic Purpura
5.5.4. Sex- Specific Cases of the Thrombotic Thrombocytopenic Purpura
5.5.5. Diagnosed Cases of the Thrombotic Thrombocytopenic Purpura
5.5.6. Treatable Cases of the Thrombotic Thrombocytopenic Purpura
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Thrombotic Thrombocytopenic Purpura
5.6.3. Sub-Type Specific cases of the Thrombotic Thrombocytopenic Purpura
5.6.4. Sex- Specific Cases of the Thrombotic Thrombocytopenic Purpura
5.6.5. Diagnosed Cases of the Thrombotic Thrombocytopenic Purpura
5.6.6. Treatable Cases of the Thrombotic Thrombocytopenic Purpura
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Thrombotic Thrombocytopenic Purpura
5.7.3. Sub-Type Specific cases of the Thrombotic Thrombocytopenic Purpura
5.7.4. Sex- Specific Cases of the Thrombotic Thrombocytopenic Purpura
5.7.5. Diagnosed Cases of the Thrombotic Thrombocytopenic Purpura
5.7.6. Treatable Cases of the Thrombotic Thrombocytopenic Purpura
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Thrombotic Thrombocytopenic Purpura
5.8.3. Sub-Type Specific cases of the Thrombotic Thrombocytopenic Purpura
5.8.4. Sex- Specific Cases of the Thrombotic Thrombocytopenic Purpura
5.8.5. Diagnosed Cases of the Thrombotic Thrombocytopenic Purpura
5.8.6. Treatable Cases of the Thrombotic Thrombocytopenic Purpura
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Thrombotic Thrombocytopenic Purpura
5.9.3. Sub-Type Specific cases of the Thrombotic Thrombocytopenic Purpura
5.9.4. Sex- Specific Cases of the Thrombotic Thrombocytopenic Purpura
5.9.5. Diagnosed Cases of the Thrombotic Thrombocytopenic Purpura
5.9.6. Treatable Cases of the Thrombotic Thrombocytopenic Purpura
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Thrombotic Thrombocytopenic Purpura
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Thrombotic Thrombocytopenic Purpura
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Thrombotic Thrombocytopenic Purpura : 7MM Market Analysis
12.1. 7MM Market Size of Thrombotic Thrombocytopenic Purpura
12.2. 7MM Percentage Share of drugs marketed for Thrombotic Thrombocytopenic Purpura
12.3. 7MM Market Sales of Thrombotic Thrombocytopenic Purpura by Products
13. Thrombotic Thrombocytopenic Purpura : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Thrombotic Thrombocytopenic Purpura in United States
13.1.2. Percentage Share of drugs marketed for Thrombotic Thrombocytopenic Purpura in United States
13.1.3. Market Sales of Thrombotic Thrombocytopenic Purpura by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Thrombotic Thrombocytopenic Purpura in Germany
13.2.1.2. Percentage Share of drugs marketed for Thrombotic Thrombocytopenic Purpura in Germany
13.2.1.3. Market Sales of Thrombotic Thrombocytopenic Purpura by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Thrombotic Thrombocytopenic Purpura in France
13.2.2.2. Percentage Share of drugs marketed for Thrombotic Thrombocytopenic Purpura in France
13.2.2.3. Market Sales of Thrombotic Thrombocytopenic Purpura by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Thrombotic Thrombocytopenic Purpura in Italy
13.2.3.2. Percentage Share of drugs marketed for Thrombotic Thrombocytopenic Purpura in Italy
13.2.3.3. Market Sales of Thrombotic Thrombocytopenic Purpura by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Thrombotic Thrombocytopenic Purpura in Spain
13.2.4.2. Percentage Share of drugs marketed for Thrombotic Thrombocytopenic Purpura in Spain
13.2.4.3. Market Sales of Thrombotic Thrombocytopenic Purpura by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Thrombotic Thrombocytopenic Purpura in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Thrombotic Thrombocytopenic Purpura in United Kingdom
13.2.5.3. Market Sales of Thrombotic Thrombocytopenic Purpura by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Thrombotic Thrombocytopenic Purpura in Japan
13.3.2. Percentage Share of drugs marketed for Thrombotic Thrombocytopenic Purpura in Japan
13.3.3. Market Sales of Thrombotic Thrombocytopenic Purpura by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight